EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non–Small-Cell Lung Cancer.

Autor:	Giustini, Nicholas P., Pritchard, Colin C., Kamat, Nikhil V., Menon, Manoj P.
Předmět:	NON-small-cell lung carcinoma OSIMERTINIB EPIDERMAL growth factor receptors
Zdroj:	JCO Precision Oncology; 7/11/2024, Vol. 8, p1-4, 4p
Abstrakt:	Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu